ArticleLiver cancer2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).
Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Article
- Methodological Concerns in "Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma".Liver cancer · 2026Article
- Comment on the Article "Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma".Liver cancer · 2026Article
- The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma.Frontiers in immunology · 2026Article
- When Resectability Emerges After Systemic Therapy in Hepatocellular Carcinoma: A Proposed Response-Guided Consolidation Framework.Journal of hepatocellular carcinoma · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Outcomes of patients with unresectable hepatocellular carcinoma (HCC) who achieve clinical complete response (cCR) to PD-1 inhibitor-based combination therapy are unclear. This study aimed to explore whether cCR after combination therapy is an accurate and reliable prognostic indicator and to identify predictors of cCR and pathological complete response that could aid in managing patients with HCC. Methods: Data were analyzed retrospectively for 1,266 patients with initially unresectable HCC who received combination therapy involving PD-1 inhibitors and interventional therapy at 23 medical centers across China between 2019 and 2023. Survival was compared between patients who showed cCR or not after combination therapy, and subgroup analyses differentiated further between patients who experienced pathological complete response or not after combination therapy and patients who subsequently underwent curative hepatectomy or not. Results: Among all patients, 200 (15.8%) achieved cCR after combination therapy, and 360 (28.4%) underwent curative hepatectomy following combination therapy. Survival rates at 3 years were significantly higher among those who achieved cCR after combination therapy than those who did not, whether overall survival (82.4 vs. 35.9%; HR 0.15, 95% CI: 0.12-0.19) or progression-free survival (63.4 vs. 26.4%; HR 0.19, 95% CI: 0.16-0.23). Similar results were obtained with subsets of patients matched through propensity scoring based on baseline characteristics. Patients who underwent hepatectomy showed significantly longer overall and progression-free survival than those who did not; and among those who underwent surgery, cCR after combination therapy was associated with significantly better survival. Multivariable analysis identified the following independent predictors of cCR: α-fetoprotein <400 ng/mL, single tumor, absence of macrovascular invasion, absence of extrahepatic metastasis, and combined with anti-angiogenic agents. cCR correlated strongly with pathological complete response (Φ = 0.633) and independently predicted it (OR 17.43, 95% CI: 5.69-53.35). Conclusions: cCR following PD-1 inhibitor-based combination therapy is associated with excellent survival in patients with unresectable HCC. Such response and the clinical characteristics that predict it may be useful for assessing prognosis after combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.